Recombinant human IL-11 was Food and Drug Administration approved in 1997 and marketed as Neumega (oprelvekin, Wyeth Pharmaceuticals) as the first platelet growth factor to treat severe thrombocytopenia or prevent severe thrombocytopenia following chemotherapy. The gene discussed is IL11; the disease is Thrombocytopenia.